Trending...
- ACC Hosts Cybersecurity Lunch & Learn for Syracuse Area Business Leaders and IT Professionals
- Suzy Chase Created the Mixtape Podcast. Now She's Bringing Back Intentional Music Listening
- Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company").
The investigation concerns whether Atara Biotherapeutics, Inc. and certain of its officers and/or directors have engaged in securities fraud.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
More on Nyenta.com
Atara announced on January 16, 2025, that it had received "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen."
According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO."
The FDA took the additional step of placing a clinical hold on the biotech's active Investigational New Drug applications due to the same manufacturing concerns that led to Ebvallo's rejection. In addition to Ebvallo, the hold also affected the company's allogeneic CD19 CAR T therapy ATA3219, which was testing for non-Hodgkin's lymphoma and systemic lupus erythematosus. Atara had to suspend screening and enrollment of new study patients in both programs. Only those already enrolled in trials who could "potentially derive clinical benefit" can continue receiving treatment under ongoing study protocols.
On January 16, 2025, the stock fell $4.82 per share, to close at $7.62, a decline of 39%.
The company has subsequently announced, on January 27, 2025, that it would cut 50% of its workforce by June of this year.
More on Nyenta.com
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company").
The investigation concerns whether Atara Biotherapeutics, Inc. and certain of its officers and/or directors have engaged in securities fraud.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
More on Nyenta.com
- Card makers turn to Pink and Main for tools to support their craft
- Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
- EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
- Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
- AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
Atara announced on January 16, 2025, that it had received "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen."
According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO."
The FDA took the additional step of placing a clinical hold on the biotech's active Investigational New Drug applications due to the same manufacturing concerns that led to Ebvallo's rejection. In addition to Ebvallo, the hold also affected the company's allogeneic CD19 CAR T therapy ATA3219, which was testing for non-Hodgkin's lymphoma and systemic lupus erythematosus. Atara had to suspend screening and enrollment of new study patients in both programs. Only those already enrolled in trials who could "potentially derive clinical benefit" can continue receiving treatment under ongoing study protocols.
On January 16, 2025, the stock fell $4.82 per share, to close at $7.62, a decline of 39%.
The company has subsequently announced, on January 27, 2025, that it would cut 50% of its workforce by June of this year.
More on Nyenta.com
- BestDoc Launches AI Call Center for Healthcare
- Reality Fractures in New Sci-Fi Technothriller 2nd Iteration by A.P. Blanchard
- Deep Spiritual Ambient: Zara Releases Sufi Laments Album
- Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
- Grange Insurance Association to Rebrand as Granwest Insurance on July 1, 2026
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
- Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- Big Bank Earnings: AI Trading Drives 107% Annualized Returns for US Financial Institutions (JPM, GS)
- Sutra House Publishes Return of the Mary Celeste by Stephen Hayes
- Growing Demand for Prenatal Massage in NYC Reflects Focus on Maternal Wellness
- New Creative Digital Magazine Feeling Creative? Reaches 5,000 Monthly Readers in First Six Mo
- ApologyFlowers.com Launches Free Screw-Up Calculator to Help Men Navigate Relationship Repair
- InterMountain Management Announces the Re-opening of Holiday Inn Express & Suites Alexandria
- ForHumanity / Assessed Intelligence Announce Collaboration Agreement to Advance Secure & Responsibl
- CB Stuffer Expands New England Footprint with Launch at Common Man Roadside in Hooksett, NH
- Contracting Resources Group Named to the 2026 Inc. Regionals: Mid-Atlantic List
- Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
- Primoris Releases Eternal Velocity — A High‑Impact Techno Album Fueled by Dark Energy
- Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
- Celebrate World Creativity and Innovation Day with the Launch of the Book: World Innovators Cup
- Water mist fire extinguishing systems -Markets. Technologies, Competition 2026 to 2035
- All American Home Renovators: Transforming Bathrooms into Masterpieces, One Home at a Time
- Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
- Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation